PFE Stock: Cleararc Capital Has Decreased Pfizer Stake by $610,750 as Stock Value Declined

0
2792

Venbio Select Advisor Llc increased its stake in Ovascience Inc (OVAS) by 258.09% based on its latest 2017Q3 regulatory filing with the SEC. Venbio Select Advisor Llc bought 808,636 shares as the company’s stock declined 13.16% while stock markets rallied. The institutional investor held 1.12 million shares of the major pharmaceuticals company at the end of 2017Q3, valued at $1.59M, up from 313,316 at the end of the previous reported quarter. Venbio Select Advisor Llc who had been investing in Ovascience Inc for a number of months, seems to be bullish on the $49.99M market cap company. The stock decreased 2.10% or $0.03 during the last trading session, reaching $1.4. About 714,860 shares traded or 52.05% up from the average. OvaScience, Inc. (NASDAQ:OVAS) has declined 82.79% since January 1, 2017 and is downtrending. It has underperformed by 99.49% the S&P500.

Cleararc Capital Inc decreased its stake in Pfizer Inc (PFE) by 9.95% based on its latest 2017Q3 regulatory filing with the SEC. Cleararc Capital Inc sold 17,450 shares as the company’s stock declined 3.45% while stock markets rallied. The institutional investor held 157,955 shares of the health care company at the end of 2017Q3, valued at $5.64M, down from 175,405 at the end of the previous reported quarter. Cleararc Capital Inc who had been investing in Pfizer Inc for a number of months, seems to be less bullish one the $215.90B market cap company. The stock decreased 0.41% or $0.15 during the last trading session, reaching $36.22. About 11.42M shares traded. Pfizer Inc. (NYSE:PFE) has declined 2.76% since January 1, 2017 and is downtrending. It has underperformed by 19.46% the S&P500.

Venbio Select Advisor Llc, which manages about $380.08 million and $1.29B US Long portfolio, decreased its stake in Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) by 175,000 shares to 1.78M shares, valued at $9.32 million in 2017Q3, according to the filing. It also reduced its holding in Tesaro Inc (NASDAQ:TSRO) by 205,311 shares in the quarter, leaving it with 195,092 shares, and cut its stake in Immunomedics Inc (Call) (NASDAQ:IMMU).

Among 6 analysts covering OvaScience (NASDAQ:OVAS), 2 have Buy rating, 1 Sell and 3 Hold. Therefore 33% are positive. OvaScience had 12 analyst reports since August 11, 2015 according to SRatingsIntel. The stock has “Hold” rating by Oppenheimer on Thursday, June 22. Oppenheimer maintained OvaScience, Inc. (NASDAQ:OVAS) rating on Wednesday, October 21. Oppenheimer has “Outperform” rating and $16 target. The firm earned “Market Perform” rating on Monday, November 9 by Leerink Swann. Oppenheimer maintained the shares of OVAS in report on Wednesday, September 30 with “Outperform” rating. The firm has “Mkt Perform” rating given on Tuesday, September 29 by JMP Securities. The rating was maintained by Wedbush with “Outperform” on Tuesday, August 11. The stock of OvaScience, Inc. (NASDAQ:OVAS) earned “Perform” rating by Oppenheimer on Monday, January 25. H.C. Wainwright maintained the stock with “Buy” rating in Friday, August 4 report. The firm has “Outperform” rating given on Friday, August 14 by Leerink Swann. Credit Suisse initiated OvaScience, Inc. (NASDAQ:OVAS) on Thursday, January 21 with “Underperform” rating.

Investors sentiment increased to 0.85 in Q3 2017. Its up 0.19, from 0.66 in 2017Q2. It increased, as 12 investors sold OVAS shares while 14 reduced holdings. 5 funds opened positions while 17 raised stakes. 19.65 million shares or 2.14% less from 20.08 million shares in 2017Q2 were reported. Employees Retirement System Of Texas holds 90,000 shares or 0% of its portfolio. Citadel Advsrs Lc owns 0% invested in OvaScience, Inc. (NASDAQ:OVAS) for 58,645 shares. Deutsche Bancorp Ag invested in 6,833 shares or 0% of the stock. Tortoise Investment Ltd Com invested in 0% or 3,402 shares. Prelude Mgmt Lc has 200 shares for 0% of their portfolio. Northern Capital Limited Liability holds 0.04% or 91,065 shares. Geode Mngmt Lc stated it has 0% in OvaScience, Inc. (NASDAQ:OVAS). 1,465 were reported by Tru Company Of Vermont. Blackrock Inc invested in 457,841 shares. Jennison Assoc Ltd Com has 2.19M shares for 0% of their portfolio. The Virginia-based Third Security Limited Liability Co has invested 0.03% in OvaScience, Inc. (NASDAQ:OVAS). Barclays Public Lc owns 90 shares for 0% of their portfolio. Ecor1 Capital reported 0.66% stake. Wells Fargo And Communication Mn stated it has 0% of its portfolio in OvaScience, Inc. (NASDAQ:OVAS). Adage Partners Limited Com holds 1.28 million shares or 0% of its portfolio.

Among 21 analysts covering Pfizer (NYSE:PFE), 9 have Buy rating, 1 Sell and 11 Hold. Therefore 43% are positive. Pfizer had 67 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by Jefferies on Tuesday, June 14 with “Buy”. Deutsche Bank maintained Pfizer Inc. (NYSE:PFE) on Wednesday, October 28 with “Buy” rating. The rating was upgraded by Cowen & Co to “Outperform” on Tuesday, October 20. On Friday, December 2 the stock rating was initiated by Guggenheim with “Neutral”. As per Wednesday, November 2, the company rating was downgraded by BMO Capital Markets. The company was maintained on Monday, July 10 by Cowen & Co. The firm has “Neutral” rating given on Friday, March 24 by Societe Generale. The rating was upgraded by SunTrust to “Neutral” on Wednesday, November 25. The stock of Pfizer Inc. (NYSE:PFE) earned “Market Perform” rating by Leerink Swann on Monday, May 2. As per Thursday, July 14, the company rating was maintained by Jefferies.

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on January, 30. They expect $0.56 EPS, up 19.15% or $0.09 from last year’s $0.47 per share. PFE’s profit will be $3.34B for 16.17 P/E if the $0.56 EPS becomes a reality. After $0.67 actual EPS reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -16.42% negative EPS growth.

Cleararc Capital Inc, which manages about $7.05B and $665.83 million US Long portfolio, upped its stake in Pnc Finl Svcs Group Inc Com (NYSE:PNC) by 3,163 shares to 15,252 shares, valued at $2.06 million in 2017Q3, according to the filing. It also increased its holding in Cl C by 439 shares in the quarter, for a total of 7,747 shares, and has risen its stake in Kimco Realty Corp (NYSE:KIM).

LEAVE A REPLY

Please enter your comment!
Please enter your name here